Everpar Advisors LLC Buys Shares of 4,014 Amgen Inc. (NASDAQ:AMGN)

Everpar Advisors LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,014 shares of the medical research company’s stock, valued at approximately $1,156,000.

Other large investors have also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amgen by 1.7% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares during the last quarter. Diversified Trust Co raised its position in shares of Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the last quarter. Provence Wealth Management Group grew its position in Amgen by 11.9% during the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after purchasing an additional 154 shares during the last quarter. Nicolet Advisory Services LLC increased its stake in Amgen by 4.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares in the last quarter. Finally, Platform Technology Partners raised its holdings in shares of Amgen by 7.4% in the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after buying an additional 402 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AMGN shares. SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Oppenheimer reissued an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Finally, Raymond James began coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.05.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.69% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of Amgen stock traded up $7.01 during trading hours on Wednesday, reaching $307.31. 2,858,665 shares of the company’s stock were exchanged, compared to its average volume of 2,909,728. The business has a fifty day moving average of $275.65 and a two-hundred day moving average of $281.74. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The company has a market capitalization of $164.85 billion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same period in the previous year, the firm posted $3.98 EPS. The business’s revenue for the quarter was up 22.0% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.